TRI invests in a wide range of product and enabling technology opportunities worldwide, and offers several advantages as a preferred investment partner:

Broad Investment Scope
TRI seeks investments and discovery collaborations worldwide. Our strategic investment mandate means that while we will consider product, target and technology opportunities at any stage, our focus is on start-up/seed rounds, through Series "A" financing. We will also consider later rounds of investment (second, third, or mezzanine) where this assists in driving promising projects to conclusion.

Long-Term Horizon
TRI takes a longer-term view of its investments, preferring to see returns in the form of products, technologies or targets to complement and extend Takeda's own R&D activities. This means that TRI investments are less dilutive than traditional sources of venture funding.

Capacity and Reach of a Global Company
Our parent company, TPC, is the largest pharmaceutical company in Japan and among the leaders in the world. This enables us to provide our portfolio companies with access to a global pharmaceutical environment through TPC's multinational research, development and marketing capabilities, and the company's extensive network of collaborations.

Flexibility
TRI seeks not only venture investments, but also preclinical research alliances and collaborations. Opportunities that do not fit TRI's equity investment parameters, but are of scientific interest to TPC, are evaluated as potential strategic alliance and research collaborations. TRI is able to leverage the significant annual research budget of TPC to sponsor such collaborations.

Targeted Resources
TRI is fully supported by its holding company, Takeda America Holdings, Inc, enabling us to focus our resources on identifying, analyzing and supporting investment opportunities.

Respect for Autonomy
TRI respects the autonomy of the institutions it invests in, and will usually seek passive investment terms, providing strategic management input only when requested. However, TRI will require board observer rights and will usually request scientific review rights when appropriate.